Multiparametric magnetic resonance imaging outperforms the prostate cancer prevention trial risk calculator in predicting clinically significant prostate cancer

Cancer

Volumn 120, Issue 18, 2014, Pages 2876-2882

  Salami, Simpa S ^a   Vira, Manish A ^a   Turkbey, Baris ^b   Fakhoury, Mathew ^a   Yaskiv, Oksana ^b   Villani, Robert ^a   Ben Levi, Eran ^a   Rastinehad, Ardeshir R ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Nomogram; Prostate cancer screening; Prostate fusion biopsy; Prostate imaging; Risk calculator

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PREDICTION; PROSTATE CANCER; PROSTATE CANCER PREVENTION TRIAL RISK CALCULATOR; PROSTATE SIZE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CANCER STAGING; FOLLOW UP; LARGE CORE NEEDLE BIOPSY; METABOLISM; METHODOLOGY; MIDDLE AGED; NOMOGRAM; PRIMARY PREVENTION; PROGNOSIS; PROSTATE CANCER SCREENING; PROSTATE FUSION BIOPSY; PROSTATE IMAGING; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; RISK CALCULATOR; STATISTICS;

NOMOGRAM; PROSTATE CANCER SCREENING; PROSTATE FUSION BIOPSY; PROSTATE IMAGING; RISK CALCULATOR;

ADENOCARCINOMA; AGED; BIOPSY, LARGE-CORE NEEDLE; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PRIMARY PREVENTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROC CURVE;

EID: 84908046915     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28790     Document Type: Article

References (21)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990.
2. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
3. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66-70.
4. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157: 120-134.
5. Williams SB, Salami S, Regan MM, et al. Selective detection of his-tologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer. 2012;118:2651-2658.
6. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
7. Ankerst DP, Boeck A, Freedland SJ, et al. Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2014;32:185-191.
8. Abd-Alazeez M, Kirkham A, Ahmed HU, et al. Performance of mul-tiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis. 2014;17:40-46.
9. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818-1824.
10. Rastinehad AR, Baccala AA, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on mul-tiparametric magnetic resonance imaging. J Urol. 2011;185:815-820.
11. Rastinehad AR, Turkbey B, Salami SS, et al. Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy [published online ahead of print December 4, 2013]. J Urol. 2013. doi:10.1016/j.juro.2013.12.007.
12. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-757.
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
14. Nam RKR, Kattan MWM, Chin JLJ, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29:2959-2964.
15. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186:1830-1834.
16. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(1 suppl):S12-S17; discussion S17-S18.
17. Johansson J-E, Andren O, Andersson S-O, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
18. Abd-Alazeez M, Ahmed HU, Arya M, et al. The accuracy of multi-parametric MRI in men with negative biopsy and elevated PSA level-can it rule out clinically significant prostate cancer [serial online]? Urol Oncol. 2014;32:45.e17-45.e22.
19. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011;186: 1281-1285.
20. Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713-719.
21. Eyre SJ, Ankerst DP, Wei JT, et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol. 2009;182:2653-2658.